- Home
- HURA vs AXR Comparison
HURA vs AXR Comparison
Compare HURA & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- AXR
- Stock Information
- Founded
- HURA 2009
- AXR 1961
- Country
- HURA United States
- AXR United States
- Employees
- HURA N/A
- AXR N/A
- Industry
- HURA
- AXR Homebuilding
- Sector
- HURA
- AXR Real Estate
- Exchange
- HURA Nasdaq
- AXR Nasdaq
- Market Cap
- HURA 193.8M
- AXR 188.7M
- IPO Year
- HURA N/A
- AXR N/A
- Fundamental
- Price
- HURA $3.35
- AXR $36.83
- Analyst Decision
- HURA
- AXR
- Analyst Count
- HURA 0
- AXR 0
- Target Price
- HURA N/A
- AXR N/A
- AVG Volume (30 Days)
- HURA 77.7K
- AXR 19.6K
- Earning Date
- HURA 11-14-2024
- AXR 12-09-2024
- Dividend Yield
- HURA N/A
- AXR N/A
- EPS Growth
- HURA N/A
- AXR N/A
- EPS
- HURA N/A
- AXR 1.76
- Revenue
- HURA N/A
- AXR $60,171,000.00
- Revenue This Year
- HURA N/A
- AXR N/A
- Revenue Next Year
- HURA N/A
- AXR N/A
- P/E Ratio
- HURA N/A
- AXR $21.69
- Revenue Growth
- HURA N/A
- AXR 24.69
- 52 Week Low
- HURA $2.84
- AXR $15.88
- 52 Week High
- HURA $17.36
- AXR $38.93
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- AXR 66.09
- Support Level
- HURA N/A
- AXR $31.27
- Resistance Level
- HURA N/A
- AXR $32.05
- Average True Range (ATR)
- HURA 0.00
- AXR 2.20
- MACD
- HURA 0.00
- AXR 0.44
- Stochastic Oscillator
- HURA 0.00
- AXR 78.19
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve the obtaining of approvals and the sale of both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.